Wild-type p53-induced phosphatase 1 promotes vascular smooth muscle cell proliferation and neointima hyperplasia after vascular injury via p-adenosine 5′-monophosphate-activated protein kinase/mammalian target of rapamycin complex 1 pathway
- 1 November 2019
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Hypertension
- Vol. 37 (11), 2256-2268
- https://doi.org/10.1097/hjh.0000000000002159
Abstract
Objectives: Vascular smooth muscle cell (VSMC) proliferation is a crucial cause of vascular neointima hyperplasia and restenosis, thus limiting the long-term efficacy of percutaneous vascular intervention. We explored the role of wild-type p53-induced phosphatase 1 (Wip1), a potent regulator of tumorigenesis and atherosclerosis, in VSMC proliferation and neointima hyperplasia. Methods and results: Animal model of vascular restenosis was established in wild type C57BL/6J and VSMC-specific Tuberous Sclerosis 1 (TSC1)-knockdown mice by wire injury. We observed increased protein levels of Wip1, phospho (p)-S6 Ribosomal Protein (S6)(Ser235/236), p-4EBP1(Thr37/46) but decreased p-adenosine 50'-monophosphate-activated protein kinase (AMPK)alpha(Thr172) both in carotid artery at day 28 after injury and in VSMCs after 48 h of platelet derived growth factor-BB (PDGF-BB) treatment. By using hematoxylin-eosin staining, Ki-67 immunohistochemical staining, cell counting kit-8 assay and Ki-67 immunofluorescence staining, we found Wip1 antagonist GSK2830371 (GSK) or mammalian target of rapamycin complex 1 (mTORC1) inhibitor rapamycin both obviously reversed the neointima formation and VSMC proliferation induced by wire injury and PDGF-BB, respectively. GSK also reversed the increase in mRNA level of Collagen I after wire injury. However, GSK had no obvious effects on VSMC migration induced by PDGF-BB. Simultaneously, TSC1 knockdown as well as AMPK inhibition by Compound C abolished the vascular protective and anti-proliferative effects of Wip1 inhibition. Additionally, suppression of AMPK also reversed the declined mTORC1 activity by GSK. Conclusion: Wip1 promotes VSMC proliferation and neointima hyperplasia after wire injury via affecting AMPK/mTORC1 pathway.This publication has 52 references indexed in Scilit:
- NeoatherosclerosisCirculation: Cardiovascular Interventions, 2012
- AMPKα2 Deletion Exacerbates Neointima Formation by Upregulating Skp2 in Vascular Smooth Muscle CellsCirculation Research, 2011
- Wip1 promotes RUNX2-dependent apoptosis in p53-negative tumors and protects normal tissues during treatment with anticancer agentsProceedings of the National Academy of Sciences of the United States of America, 2011
- Adiponectin Induces Vascular Smooth Muscle Cell Differentiation via Repression of Mammalian Target of Rapamycin Complex 1 and FoxO4Arteriosclerosis, Thrombosis, and Vascular Biology, 2011
- In-Stent Restenosis in the Drug-Eluting Stent EraJournal of Invasive Cardiology, 2010
- Rapamycin Regulates Endothelial Cell Migration through Regulation of the Cyclin-dependent Kinase Inhibitor p27Kip1Online Journal of Public Health Informatics, 2010
- WIP1 phosphatase at the crossroads of cancer and agingTrends in Biochemical Sciences, 2010
- p38MAPK Controls Expression of Multiple Cell Cycle Inhibitors and Islet Proliferation with Advancing AgeDevelopmental Cell, 2009
- Recurrent Initiation: A Mechanism for Triggering p53 Pulses in Response to DNA DamageMolecular Cell, 2008
- Wip1 Phosphatase Regulates p53-Dependent Apoptosis of Stem Cells and Tumorigenesis in the Mouse IntestineCell Stem Cell, 2007